Abstract
The advent of dose optimization has led to a paradigm shift in oncology clinical trials to find the optimal biologic dose (OBD). Phase 1/2 trials with randomized doses can facilitate additional investigation of the identified OBD in a targeted population by incorporating safety and efficacy data. We propose to compare randomized doses by extending the Bayesian optimal interval phase 1/2 (BOIN12) approach, an OBD-finding design in which a utility is used to account for risk-benefit trade-offs. Specifically, we used the BOIN12 standardized mean utilities in a hypothesis testing framework, in which frequentist and Bayesian inference were evaluated to compare the standardized mean utilities across doses and identify the OBD. We performed simulation studies and a hypothetical oncology study to compare the proposed BOIN12 utility-based extension (U-MET) design with an empirical design. The results demonstrated that the U-MET design has satisfactory operating characteristics for selecting the OBD. We recommend using the U-MET design as the primary dose comparison approach, or alternatively as supportive evidence, for optimal dose selection.
Disclaimer
As a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also.Funding
The author(s) reported there is no funding associated with the work featured in this article.